ABVC — ABVC BIOPHARMA, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1173313 ·
Last close
$0.94
Market Cap
$25.36M
52W High
$2.96
52W Low
$0.71
ADV30
39,898
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | 0 | -779,526 | -736,934 | 19,400,715 | 31,944 | 7,131,155 |
| Mar 2026 | 0 | 0 | -1,572,472 | -1,560,242 | 19,732,528 | 140,324 | 6,904,071 |
| Dec 2025 | -795,950 | -795,950 | -2,994,861 | -3,562,944 | 21,062,203 | 681,480 | 7,764,723 |
| Sep 2025 | 0 | 0 | -1,964,360 | -2,042,463 | 21,176,299 | 192,068 | 6,683,592 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-3,522,401
Investing CF
$162,581
Financing CF
$2,237,393
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.31
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-79,155,537
Inventory
$11,460
Receivables
$165,806
ST Investments
$62,420
EBIT TTM
$-8,240,567
Pretax Income TTM
$-8,395,777
Interest Exp TTM
$155,210
Analysts
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -7,151,259 | -7,908,554 | 21,062,203 | 7,764,723 | 11,111,861 | -2,986,299 |
| Dec 2024 | 509,589 | -4,705,242 | -4,902,878 | 7,539,907 | 6,815,948 | 1,226,140 | -1,809,145 |
| Dec 2023 | 152,430 | -6,766,734 | -7,788,050 | 7,784,499 | 6,531,026 | 1,554,110 | -4,186,848 |
| Dec 2022 | 969,783 | -15,114,412 | -16,423,239 | 9,579,574 | 6,343,435 | 3,098,585 | -7,398,391 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$133,341
NetIncome TTM
$-7,106,633
OpCashFlow TTM
—
Assets (Latest)
$19,400,715
Forward EPS
$-0.44
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BIOE | Bio Essence Corp | $25.29M | $0.47 | — |
| AARD | Aardvark Therapeutics, Inc. | $25.17M | $1.15 | — |
| CLCS | Cell Source, Inc. | $25.14M | $0.37 | — |
| BETRF | BetterLife Pharma Inc. | $25.64M | $0.15 | — |
| ACET | Adicet Bio, Inc. | $26.03M | $2.78 | — |
News headlines (Yahoo Finance, 1h cache)
/C O R R E C T I O N - WallachBeth Capital LLC/
2026-11-02 15:00 · Yahoo
ABVC BioPharma Announces Closing of Private Placement Offering of Original Issue Discount Senior Convertible Promissory Notes for Gross Proceeds of $3.39 Million
2026-11-02 14:30 · Yahoo
ABVC BioPharma, Inc. Announces Planned Spin-Off of BioKey (Cayman), Inc. Through Dividend Distribution of BioKey Shares to ABVC Shareholders
2026-06-23 12:30 · Yahoo
ABVC BioPharma Reports 2025 Form 10-K
2026-03-03 22:00 · Yahoo
ABVC BioPharma Provides Corporate and Structural Update
2026-02-24 13:30 · Yahoo
ABVC BioPharma Highlights Safety Profile of Its Plant-Based ADHD Candidate Amid Growing Concerns About Psychiatric Polypharmacy in the United States
2025-12-02 13:30 · Yahoo
ABVC BioPharma Highlights Strengthened Operations at BioKey's 28,176-sq.-ft. Silicon Valley Facility, Featuring U.S.-Based Multi-Product Capabilities Including Functional Foods, and Expansion Outlook
2025-11-26 13:30 · Yahoo
ABVC Receives US$250,000 From ForSeeCon; Vitargus(R) Total Licensing Fee up to US$33.5 Million; US$816,000 Already Received
2025-11-21 13:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.